FMC Corporation Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. FMC Corporation is a global agricultural sciences company operating in a single segment, developing crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The company is currently executing "Project Foundation," a comprehensive cost-optimization plan, and is in the process of divesting its commercial business in India, which is classified as held for sale.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $758.6 million | $791.4 million |
| Gross Margin | $246.6 million (32.5%) | $316.7 million (40.0%) |
| Net Loss (GAAP) | $(281.3) million | $(15.5) million |
| Diluted EPS | $(2.25) | $(0.12) |
| Operating Cash Flow | $(600.9) million | $(545.0) million |
| Total Debt | $4,533.6 million | $4,074.9 million (Dec 2025) |
| Cash and Equivalents | $390.9 million | $584.5 million (Dec 2025) |
| Adjusted EBITDA (Non-GAAP) | $72.1 million | $119.7 million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 4% year-over-year, driven by a 6% price decline due to competitive pressure on legacy products and lower pricing for diamide partners. This was partially offset by a 2% volume increase, particularly in EMEA and North America.
- Margin Compression: Gross margin percentage dropped from 40% to 32.5%, attributed to competitive pricing, tariffs, and unfavorable raw material costs.
- Restructuring Charges: Restructuring and other charges increased significantly to $77.0 million (from $17.8 million), primarily due to $90.1 million in charges related to "Project Foundation," including $64.7 million in non-cash asset write-offs.
- Tax Provision: A $112.1 million tax provision resulted in a negative effective tax rate of -75.1%, largely driven by a $123 million increase in valuation allowance for deferred tax assets in Switzerland.
- Discontinued Operations: Losses from discontinued operations increased to $19.9 million, driven by legal reserves and environmental liabilities.
Guidance, Outlook, and Risks
- Strategic Review: The Board has authorized an exploration of strategic options, including the potential sale of the company, to enhance shareholder value.
- Project Foundation: The company expects total pre-tax restructuring charges of $560 million to $635 million over the life of the program, with cash expenditures of $130 million to $155 million expected in 2026.
- Dividend Reduction: The quarterly dividend was reduced to $0.08 per share in October 2025 to prioritize debt reduction. No share repurchases are anticipated in 2026 under the public program due to credit agreement restrictions.
- India Divestiture: The sale of the India commercial business is expected to conclude in 2026. Proceeds are planned to be used for debt paydown.
- Legal Proceedings: The company is defending against a securities class action lawsuit alleging misstatements regarding channel inventory, sales practices, and the India divestment.
- Debt Covenants: On April 16, 2026, the company amended its credit agreement to provide covenant relief, raising the maximum leverage ratio to 6.75 through late 2027 and lowering the minimum interest coverage ratio to 2.00.
Investor Verification Checklist
- Verify the timeline and expected proceeds from the India commercial business divestiture.
- Monitor the progress of the strategic review process and potential sale of the company.
- Track the execution of "Project Foundation" and the realization of expected cost savings versus the $560-$635 million in total charges.
- Assess the impact of the $123 million Swiss valuation allowance on future effective tax rates.
- Review the status of the securities class action litigation and potential financial exposure.
- Confirm compliance with the amended debt covenants, specifically the leverage and interest coverage ratios.